Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals

Table 1 Characteristics of HIV-HCV coinfected patie nts treated with antiretroviral therapy at the time of liver biopsy (parameters collected the day of the liver biopsy or during the week before)

	n=184
Median age at biopsy (IQR), years	41 (36-45)
Male, n (%)	154 (84)
Ethnicity, n (%)
Caucasian	163 (89)
Black	21 (11)
Intravenous drug use, n (%)	127 (61)
Alcohol use, n (%)*	67 (36)
Median duration of HIV diagnosis (IQR, years	11 (7-14)
Median CD4 cell counts/mm³ (IQR)	321 (227-461)
Undetectable HIV RNA⁺, n (%)	119 (67)
HCV genotype⁺⁺, n (%)
1	98 (55)
2	10 (6)
3	47 (26)
4	24 (13)
Median HCV RNA (IQR), log₁₀ KIU/ml⁺⁺⁺	6.18 (5.76-6.60)
Median laboratory variables (IQR), U/l
ALT	83 (47-128)
AST	65 (43-97)
Alkaline phosphatase	89 (71-113)
GGT	80 (42-160)
Median glycemia (IQR), mmol/l	4.8 (4.3-5.3)
Glycemia 5.6mmol/l⁺, n (%)	33 (19)
Glycemia7.0mmol/l⁺, n (%)	7 (4)
Median total cholesterol (IQR), mmol/l	4.20 (3.54-5.10)
Median triglyceridemia (IQR), mmol/l	1.49 (0.99-2.10)
Triglyceridemia 1.7mmol/l⁺, n (%)	60 (36)
Median duration of antiretroviral therapy (IQR), months	58 (28-94)
Median cumulative exposure to antiretrovirals (IQR), months
NRTI	56 (28-90)
NNRTI	16 (9-31)
PI	23 (12-40)
Combination of ART at liver biopsy, n (%)
2 NRTI+1 PI	93 (51)
2 NRTI+1 NNRTI	36 (20)
1 or 2 NRTI	31 (16)
3 NRTI	17 (9)
Other regimens	7 (4)

⁺ proportions calculated on available data.
⁺ Data missing for 6 patients; ⁺⁺ Data missing for 5 patients; ⁺⁺⁺ Data missing for 36 patients; Data missing for 11 patients; Data missing for 18 patients.
*Alcohol: no quantification was available.
Abbreviations: ALT, alanine transaminase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transpeptidase; IQR, interquartile range; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.

ISSN: 1756-0500